ArticleInternational journal of clinical oncology2013
The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer.
Article in International journal of clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of liver resection in patients with metastatic breast cancer: a systematic review examining the survival impact.Irish journal of medical science · 2018Pooled it
- A nomogram and risk stratification system for predicting survival in T1-2N0-1 breast cancer patients with liver metastasis in females: a population-based study.Biomedical engineering online · 2024Article
- Survival nomogram for patients withCancer pathogenesis and therapy · 2023Article
- Prognostic and clinicopathological significance of fatty acid synthase in breast cancer: A systematic review and meta-analysis.Frontiers in oncology · 2023Review
- Breast cancer liver metastasis: Pathogenesis and clinical implications.Frontiers in oncology · 2022Review
- Risk and prognostic factors of breast cancer with liver metastases.BMC cancer · 2021Article
- Risk Factors and Survival of Patients With Liver Metastases at Initial Metastatic Breast Cancer Diagnosis in Han Population.Frontiers in oncology · 2021Article
- Prognosis and Genomic Landscape of Liver Metastasis in Patients With Breast Cancer.Frontiers in oncology · 2021Article
- A Prognostic Model for Breast Cancer With Liver Metastasis.Frontiers in oncology · 2020Article
- Prognostic factors and survival according to tumor subtype in newly diagnosed breast cancer with liver metastases: A competing risk analysis.Molecular and clinical oncology · 2019Article
- Long-term survival and cure model following liver resection for breast cancer metastases.Breast cancer research and treatment · 2018Article
- Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: a population-based study.Cancer management and research · 2018Article
- Incidence and Survival Outcomes of Breast Cancer with Synchronous Hepatic Metastases: A Population-Based Study.Journal of Cancer · 2018Article
- Hepatic arterial infusion chemotherapy for extensive liver metastases of breast cancer: efficacy, safety and prognostic parameters.Journal of cancer research and clinical oncology · 2017Article
- Article
- [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2016Article
- Prognostic impact of breast cancer subtypes in elderly patients.Breast cancer research and treatment · 2016Article
- Mechanisms involved in breast cancer liver metastasis.Journal of translational medicine · 2015Review
- Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?Breast care (Basel, Switzerland) · 2014Review
- Liver resections of isolated liver metastasis in breast cancer: results and possible prognostic factors.HPB surgery : a world journal of hepatic, pancreatic and biliary surgery · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo determine whether the inferior outcome noted with triple-negative breast cancer (TNBC) reflects a higher risk population among patients with breast cancer liver metastases.
methodsA total of 123 patients with breast cancer liver metastases diagnosed at Tianjin Medical University Cancer Hospital were included in this study. Breast cancer subtype was assigned using immunohistochemistry or fluorescence in situ hybridization: hormone receptor (HR) positive (+)/human epidermal growth factor receptor 2 (HER2) negative (-), HR+/HER2+, HR-/HER2+ and triple-negative subtype. Clinical features and survival were evaluated in different subtypes.
resultsThe median age at breast cancer diagnosis was 47 years (range, 23-67 years). Breast cancer subtype was confirmed in all patients (39.8% with HR+/HER2-, 24.4% with HR+/HER2+, 15.3% with HR-/HER2+ and 20.3% with TNBC). The median overall survival after liver metastases was 29 months (range, 4-89 months), and the overall 1-, 2- and 3-year survival rate was 68.3, 48.0 and 34.1%, respectively. Survival was found to be impacted by breast cancer subtype (P = 0.001), and was shortest for patients with TNBC. Time to liver metastases (TTLM) less than 24 months and liver metastasis lesions ≥3 were found to be important predictors of poor survival after liver metastases (P = 0.009 and 0.001, respectively).
conclusionsThe results indicate that clinical breast cancer subtype remains an independent prognostic predictor among patients with breast cancer liver metastases. Liver metastases arising from TNBC confers the worst prognosis, and novel agents capable of controlling intrahepatic and extrahepatic TNBC are needed.
Indexed as
Identifiers
22041927What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.